Previous Article | Next Article 
Molecular and Cellular Biology, October 2001, p. 6906-6912, Vol. 21, No. 20
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.20.6906-6912.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
RhoB Is Dispensable for Mouse Development, but It Modifies
Susceptibility to Tumor Formation as Well as Cell Adhesion and
Growth Factor Signaling in Transformed Cells
Ai-Xue
Liu,1
Neena
Rane,1
Jeh-Ping
Liu,2,
and
George C.
Prendergast1,3,*
The Wistar Institute,
Philadelphia,1 and The DuPont
Pharmaceuticals Company, Glenolden Laboratory,
Glenolden,3 Pennsylvania, and Center for
Neurobiology and Behavior, Columbia University, New York, New
York2
Received 20 April 2001/Returned for modification 14 June
2001/Accepted 6 July 2001
 |
ABSTRACT |
RhoB is an endosomal small GTPase that is implicated in the
response to growth factors, genotoxic stress, and farnesyltransferase inhibitors. To gain insight into its physiological functions we examined the consequences of homozygous gene deletion in the mouse. Loss of RhoB did not adversely affect mouse development, fertility, or
wound healing. However, embryo fibroblasts cultured in vitro exhibited
a defect in motility, suggesting that RhoB has a role in this process
that is conditional on cell stress. Neoplastic transformation by
adenovirus E1A and mutant Ras yielded differences in cell attachment
and spreading that were not apparent in primary cells. In addition,
transformed
/
cells displayed altered actin and proliferative
responses to transforming growth factor
. A negative modifier role
in transformation was suggested by the increased susceptibility of
/
mice to 7,12-dimethylbenz[a]anthracene-induced skin carcinogenesis and by the increased efficiency of intraperitoneal tumor formation by
/
cells. Our findings suggest that RhoB is a
negative regulator of integrin and growth factor signals that are
involved in neoplastic transformation and possibly other stress or
disease states.
 |
INTRODUCTION |
RhoB is a ubiquitous member of the
Rho family of isoprenylated small GTPases that control cytoskeletal
actin organization in cells. RhoB is closely related to RhoA, its
better-studied relative. However, RhoB differs in a number of aspects
that indicate it has unique cellular functions. First, RhoB is located
in early endosome and nuclear membranes (1, 14, 15, 20,
26). Second, RhoB appears to have a specialized role in
intracellular trafficking of cytokine receptors such as the epidermal
growth factor receptor (9). Third, unlike most small
GTPases, RhoB is short lived and is part of the immediate early
genetic response to epidermal growth factor, transforming growth factor
(TGF-
), Src activation, or genotoxic stress (5-8, 11,
12). Lastly, RhoB is a crucial target for alteration by
farnesyltransferase inhibitors, which selectively inhibit the
proliferation and survival of transformed cells (3, 4, 14,
17).
To investigate the physiological functions of RhoB, we analyzed mice in
which the rhoB gene was targeted for homozygous deletion. Loss of RhoB produced a minimal phenotype that was not associated with
any apparent effects on development, fertility, or wound healing.
However, cellular analyses revealed roles for RhoB in motility and
proliferation responses that were associated with stress conditions,
including those elicited by in vitro culture and neoplastic
transformation. Interestingly, RhoB loss in mice was associated with an
increased susceptibility to chemical carcinogenesis, and transformed
cells lacking RhoB were more efficient at forming intraperitoneal
tumors. Our findings suggest that RhoB has a negative regulatory or
modifier function in neoplastic cells.
 |
MATERIALS AND METHODS |
Construction of rhoB nullizygous mice.
The gene-targeting plasmid used to replace the single exon encoding the
murine RhoB protein by homologous recombination was generated as
follows. One-kilobase and 5.4-kb EcoRI genomic fragments from the murine rhoB locus were cloned into pBluescript
SK(+) separately, generating the plasmids pR1 and pR5. pR1 was digested with ApaI and BamHI, blunt end filled, and
ligated to a 4.8-kb XhoI-XbaI fragment containing
an internal ribosome entry site (IRES)-tau-lacZ
gene, generating pR120. pR5 was digested with BamHI and
ligated to a 1.8-kb BamHI fragment containing pGKneo, generating pR51. The final targeting plasmid was generated by ligating
a blunt-ended SalI-SpeI fragment from pR120 into
the NotI site of pR51. Standard methods were used to
electroporate Sv129 embryonic stem (ES) cells with a linearized
preparation of the targeting construct produced by SalI
digestion. Ten ES clones from 288 clones screened had undergone the
desired homologous recombination event to replace one rhoB
allele. Mouse C57B/6J blastocysts were injected by standard methods
with three different targeted ES cell clones (137, E, F). Chimeric mice
exhibiting germ line transfer of the targeted allele were obtained from
all three clones. The genotype of mice and cultured embryo fibroblasts was confirmed by PCR and Southern blot analyses as described previously (17).
Cell culture.
Mouse embryo fibroblasts (MEFs) were generated
as follows. The heads, limbs, and internal organs were removed from
embryos at E14.5 or E16.5. The carcasses were minced in Dulbecco
modified Eagle medium (DMEM; Life Technologies) and individually
trypsinized for 20 min at 37°C. Fetal bovine serum was added to stop
the trypsinization, and the cell suspension was seeded into
25-cm2 flasks containing DMEM and 10% fetal
bovine serum. Cells were maintained in the same media containing 10 U
of penicillin-streptomycin per ml. MEF cell lines generated by
cotransformation with the human oncogenic H-Ras vector pT22 and the
adenovirus E1A vector p1A/neo have been described previously
(17).
To monitor cell motility, attachment, and spreading, cells were seeded
into dishes coated overnight at 4°C with 10 µg of fibronectin (Sigma) per ml dissolved in phosphate-buffered saline (PBS). For motility, a section of a confluent cell monolayer was cleared with a
pipette tip, and the ability of cells to migrate into the cleared
section in the presence of the cell division inhibitor mitomycin C was
monitored. For spreading, 105 cells were seeded
in six-well dishes, and spread cells were photographed and counted
after various periods. For attachment, a fibronectin-coated 96-well
dish was washed with PBS and incubated for 30 min at 37°C with 1 mg
of bovine serum albumin per ml dissolved in PBS. Cells (104) were seeded into each well of the dish. At
various times after seeding, the plate was washed with PBS and cells
remaining attached were fixed for 20 min with 100 µl of 2%
paraformaldehyde per well. Fixed cells were washed once with PBS and
then stained for 20 min with 0.025% crystal violet in PBS. Stained
cells were washed gently with water, and the absorbance at 540 nm was
determined for each well using a microplate reader.
Growth curve determinations and colony formation assays performed in
soft agar culture were performed essentially as described
previously
(
3). For TGF-

response, 8,000 cells were seeded
per
well in quadruplicate in 96-well dishes and treated for 4
days with the
indicated concentrations of TGF-

(Sigma). After
the incubation
period, 10 µl of 0.5-mg/ml (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) (MTT) (Sigma) was added to each well.
Following
a 4-h incubation, cells were solubilized by overnight
treatment
at 37°C in 10% sodium dodecyl sulfide-0.01 M HCl. The
absorbance
of each well was determined at dual wavelengths of 570 and
650
nm using a microplate
reader.
Actin staining.
Cells were processed for staining with
fluorescein-phalloidin (Molecular Probes) and indirect
immunofluorescence microscopy as described previously
(22).
Western blot analysis.
Cells were washed in cold PBS and
lysed in 1% NP-40 lysis buffer. Cellular protein was quantitated by
Bradford assay, and 50 µg of cellular protein was fractionated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Gels were
analyzed by standard Western blotting methods using the
1 integrin
antibody (catalog no. 141720; Transduction Laboratories).
Detection of the primary antibody was carried out using a
chemiluminescence system for the detection of murine antibody (Amersham).
Tumor formation.
Twenty adult +/
and
/
mice were
shaved, and the dorsal epidermis was treated with a single dose of
7,12-dimethylbenz[a]anthracene (DMBA) followed by twice
weekly application of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), essentially as
described previously (10). The number and size of
papillomas on each mouse were recorded twice weekly. Tumor formation by
E1A-plus-Ras-transformed cells was assessed by implantation of 2 × 107 cells into the peritoneal cavities of
female Sv129 syngeneic mice. Mice were sacrificed 2 weeks later, and
tumor nodules in the peritoneum were counted.
 |
RESULTS |
rhoB deletion does not compromise mouse development
or fertility.
Standard homologous recombination technology was
used to delete the single exon encoding RhoB in mice. The targeting
strategy is shown in Fig. 1. The
targeting plasmid replaced an ApaI-BamHI mouse
genomic fragment containing the entire rhoB gene with
IRES-tau-lacZ and pGKneo sequences. Three
ES cell lines exhibiting the desired gene targeting event as indicated
by Southern analysis were used to generate chimeric mice, all of which
showed germ line transmission of the targeted allele (Fig. 1).
Homozygous null animals were produced at Mendelian ratios, and no
defects in development or fertility were apparent (data not shown),
suggesting that RhoB was dispensable for these processes.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Construction of rhoB nullizygous mice.
The endogenous murine rhoB locus is comprised of a
single coding exon. The gene-targeting plasmid was constructed by
replacing the 1.4-kb ApaI-BamHI fragment
of the rhoB gene with
IRES-tau-lacZ and pGKneo sequences. A
350-bp HindIII-EcoRI fragment was used to
probe Southern blots of genomic DNA digested with
HindIII to identify targeted versus endogenous alleles.
The probe recognizes a 2.6-kb HindIII band in the
endogenous allele and a 1.6-kb band in the targeted allele. A,
ApaI; B, BamHI; H,
HindIII; R, EcoRI (restriction sites are
not noted in the IRES-tau-lacZ and pGKneo
genes).
|
|
Primary
/
MEFs exhibit a defect in motility on
fibronectin.
Rho proteins regulate actin structures that are
important for the adhesion, spreading, and motility of cells.
Therefore, we compared these parameters in primary +/+ and
/
MEFs.
Attachment was assessed by comparing the number of +/+ and
/
MEFs
remaining at times after seeding equal numbers of cells into
fibronectin-coated culture dishes and washing multiple times with PBS.
Spreading was assessed by comparing the rates at which +/+ and
/
MEFs flattened on dishes after seeding. No differences were noted in these tests (data not shown). Motility was assessed by comparing the
rate at which +/+ or
/
MEFs moved into a cleared section of a
confluent monolayer in the presence of the cell division inhibitor
mitomycin C. In this assay, a defect in motility of
/
MEFs was
apparent. Within 18 h, +/+ cells had migrated into the cleared
section of the fibronectin-coated dish, whereas there was comparatively
little movement of
/
cells (Fig. 2A).
Cell motility is important during development, but as indicated above, we did not detect any phenotypic abnormalities in
/
mice. In addition, no motility defects were apparent during the healing of
various types of skin wounds generated in
/
mice (data not shown).
Thus, we interpreted the in vitro defect to be conditional on the
presence of cell stresses generated by in vitro culture. In support of
the defect observed, we noted an altered gel mobility of the
1
integrin fibronectin receptor subunit in
/
MEFs (Fig. 2B). This
observation supported the likelihood of some disruption in substratum
adhesion that could impact motility.

View larger version (111K):
[in this window]
[in a new window]
|
FIG. 2.
Defective motility of / MEFs on fibronectin and
altered gel mobility of the 1 integrin isoform. (A) Motility. The
ability of MEFs in a confluent monolayer to migrate into a section of
the dish cleared by a pipette tip was documented by photography after
18 h in the presence of the cell division inhibitor mitomycin C
(10 µM). (B) Western analysis of 1 integrin. Extracts isolated
from MEFs of the genotype indicated were analyzed by Western blotting
using a 1 integrin antibody. Note the slight reduction in the gel
mobility of the upper band in / MEFs.
|
|
Neoplastically transformed
/
MEFs exhibit altered adhesion and
spreading.
It has previously been demonstrated that RhoB is a
crucial target for alteration by farnesyltransferase inhibitors (FTIs), a class of experimental antineoplastic drugs. One of the most interesting aspects of FTIs is that they dramatically affect
transformed cells but have little effect on normal cell physiology. It
was reasoned that RhoB may have a similarly peculiar association with transformed cell physiology, perhaps due to stresses engendered by
transformation. To explore this possibility, a comparison was made of
the adhesive and motile properties of MEFs that were transformed by
adenovirus E1A plus mutant Ras (17). For clarity,
and to distinguish these cells from normal MEFs, we have used the
designation ER for E1A-plus-Ras-transformed MEFs below.
In contrast to normal MEFs, we found that ER
/
cells
displayed a significant reduction in the rate of substratum attachment
and spreading. After seeding equal numbers of cells on dishes
coated
with fibronectin, unattached cells were removed at various
times by
washing with PBS. Cells that were attached were stained
with crystal
violet and their relative number was quantitated
by absorbance at 540 nm on a plate reader. Attachment of ER

/
cells was markedly less
efficient than that of ER
+/
cells 60 min after seeding on
fibronectin (Fig.
3A). This phenotype
was
found to be associated with a reduction in the rate of cell
spreading
on fibronectin (Fig.
3B). In time course experiments,
ER

/

cells
spread significantly more slowly than ER +/

cells
after seeding on
fibronectin (Fig.
3C). The differences in spreading
that were apparent
at earlier times disappeared at later times,
when ER

/

cells were
spread in a proportion similar to that
of ER +/

cells (data not
shown). Taken together, these findings
suggested that RhoB affected
cell adhesion capacity in some manner
that was conditional on
transformation or on stresses that were
elicited by transformation.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
ER / cells display reduced attachment and spreading
on fibronectin. (A) Attachment. ER cells were seeded into six-well
dishes coated with fibronectin, and 60 min later the cells were washed
three times with PBS. Cells remaining attached were stained with
crystal violet and the optical density (OD) at 540 nm was determined to
quantitate the relative cell numbers. (B) Spreading morphology. ER
cells were photographed 60 min after seeding on fibronectin-coated
dishes. (C) Spreading time course. The relative proportion of
nonrefractile (spread) ER cells was determined at various times after
seeding on fibronectin-coated dishes.
|
|
Altered response of transformed
/
MEFs to serum and to
TGF-
.
RhoB has been reported to attenuate responses to TGF-
(5). However, we did not detect differences in the
response of
/
primary MEFs to treatment with this growth factor
(data not shown). Given the other differences in ER
/
cells, we
reasoned that transformation might uncover differences in the response
to TGF-
. It has been shown that under suboptimal serum conditions
Ras-transformed cells respond to TGF-
by forming increased numbers
of actin stress fibers through a process that is Rho dependent
(21). In growth media, ER
/
cells exhibited no
significant differences. In contrast, in the absence of serum growth
factors ER +/
cells retained a limited stress fiber network, whereas
ER
/
cells were essentially devoid of stress fibers (Fig.
4A). Under these conditions, both ER +/
and ER
/
cells responded to TGF-
by increased stress fiber
formation. However, ER
/
cells were more sensitive to TGF-
and
exhibited a robust response at lower concentrations of the growth
factor (Fig. 4A). These observations suggested that RhoB was
dispensable but that it modified the efficiency of TGF-
action.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 4.
RhoB loss alters the cytoskeletal actin and
proliferative responses to TGF- . (A) Actin response. Cells were
seeded overnight, and growth medium was replaced with DMEM containing
no serum plus the indicated concentration of TGF- . Cells were
processed for F-actin staining with fluorescein-phalloidin 24 h
later. (B) Proliferation in monolayer culture. The MTT assay was used
to monitor cell proliferation. ER cells were deprived of serum for
24 h and then fed medium without serum (control) or containing
10% serum plus the indicated concentration of TGF- . Cells were
processed for the MTT assay 72 h later. Open bars,
ER+/ cells; solid bars, ER / cells. (C)
Proliferation in soft agar culture. Cells were seeded into soft agar
culture to monitor anchorage-independent proliferation, and the number
of colonies relative to the untreated control was determined 14 days
later.
|
|
These observations were extended by evidence that ER

/

cells also
varied in their proliferative response to TGF-

. In monolayer
culture, ER

/

cells responded more robustly to serum stimulation
but were also more robustly inhibited by TGF-

(Fig.
4B). To explore
the impact of adhesion, we examined the effect of TGF-

on the
anchorage-independent growth of ER cells in soft agar culture.
Under
these conditions TGF-

also suppressed proliferation, except
that in
this case ER +/

cells were more susceptible to inhibition
than were
ER

/

cells (Fig.
4C). Thus, it appeared that adhesion
status was an
important factor in determining how RhoB impacted
proliferation. Taken together, these results indicated that RhoB
modified the response to TGF-

in a manner that was conditional
on
transformation and adhesion
parameters.
rhoB deletion promotes tumor formation.
The
ability of RhoB loss to influence proliferation and adhesion in
transformed cells suggested that it might affect tumorigenesis. To
investigate this possibility, we compared the susceptibilities of
/
mice to tumor formation by two different routes. First, we performed a
classical carcinogenesis test by initiating skin tumors with a single
application of DMBA followed by multiple applications of the tumor
promoter TPA. In this model for tumor progression, H-Ras mutation is
the major initiating event (2, 25, 27). Twenty +/
and
/
mice were tested, and the number of skin tumors on each mouse was
determined over a period of 16 weeks (Fig.
5A).
/
mice were more susceptible to
the formation of benign skin papillomas, which predominate in the
model.
/
mice bore a greater number of tumors on average, but
during the period monitored we did not note any significant difference
in tumor size or in susceptibility to carcinoma formation.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 5.
RhoB loss promotes tumor formation. (A) DMBA-induced
skin tumorigenesis. Skin tumors were initiated in 20 +/ or / mice
by a single application of DMBA and then promoted by twice weekly
applications of TPA. Mice were monitored for a period of 16 weeks. The
average numbers of tumors per mouse at various times after initiation
are shown. (B) Intraperitoneal injection of ER cells in syngeneic mice.
The average numbers of tumor nodules scored at necropsy 2 weeks after
injection of female syngeneic mice are shown.
|
|
As a second method to examine the effects of
rhoB deletion
on tumor formation, we compared the consequences of implanting
ER

/

cells into the peritoneal cavity of syngeneic animals.
In previous
experiments, ER

/

cells were shown to be similarly
efficient in
forming subcutaneous tumors in immunocompromised
scid mice
(
17). However, in experiments where ER cells were
injected
into the intraperitoneal cavity of syngeneic Sv129 mice,
we observed a
marked difference in the number of tumor nodules
formed at necropsy 2 weeks after injection (Fig.
5B). We concluded
that RhoB loss promoted
tumor
formation.
 |
DISCUSSION |
The findings of this study suggest that RhoB is a modifier of
adhesion and growth factor signals that are associated with cellular
stress, in particular stresses associated with neoplastic transformation. A defect in MEF motility was detected. This defect might relate to inappropriate integrin trafficking at some level. RhoB
has been suggested to have a specialized function in intracellular receptor trafficking (9), and differences in
1 integrin
mobility on gels suggestive of a difference in posttranslational
modification were observed. We interpreted the defect in MEF motility
to be conditional on stress, however, because (i)
/
mice developed in an apparently normal manner; (ii)
/
mice did not display any
defects in wound healing, where motility defects would be expected to
be manifested; and (iii) in vitro culture subjects MEFs to stress (for
an example, see reference 19). In support of some role in
motility, RhoB has been implicated in the delamination of neural crest
cells during chick development (18). However, the
mechanisms governing this role may have varied during evolution, insofar as stress appears to be a prerequisite for RhoB to influence cell motility in mouse cells.
Through studies of the antineoplastic properties of FTIs we have
previously documented a specialized connection between RhoB function
and neoplastic transformation. These studies indicated that FTIs act
not by eliminating RhoB function but instead by elevating a
geranylgeranylated RhoB isoform that negatively impacts the
proliferation and survival of transformed cells (3, 4, 17). This gain-of-function mechanism is compatible with
the findings of this study, which argues that RhoB has a negative regulatory or modifier function in transformed cells. FTIs may to a
large degree mediate their antitransforming effects by accentuating an
intrinsic negative regulatory function of RhoB. Previous findings suggesting a positive role for Rho proteins in transformation were
gained by the use of dominant inhibitory mutants of RhoA or RhoB
(13, 23, 24). These mutants broadly block endogenous Rho
functions by competing for a variety of Rho exchange factors. By
specifically eliminating RhoB we have shown that this Rho protein has a
negative role rather than a positive role in transformation. A
tumor-prone phenotype was revealed by the increased propensity of
rhoB null mice for DMBA-induced papilloma formation. The
results were consistent with an effect on the kinetics of tumor
initiation, but it would be premature to conclude that RhoB loss acts
in this way without additional investigation. Ongoing "oncomouse"
crosses will allow this issue to be assessed and possible tumor
suppressor or modifier roles for RhoB to be examined further.
Our findings confirm previous evidence that RhoB attenuates growth
factor responses in established cells (5, 9). A focus on
TGF-
was stimulated by observations linking RhoB to this
context-dependent regulator of transformed cell growth. TGF-
stimulates actin stress fiber formation in Ras-transformed cells in a
manner that is associated with upregulation of RhoB and RhoA and that
is reversed by the generalized Rho inhibitor C3 transferase
(21). Here we showed that although RhoB was dispensable
for TGF-
-induced stress fiber formation in transformed cells, it
sensitized the cells to this process, a result that argues for its
participation in the TGF-
response. Similarly, while RhoB loss did
not abolish the effects of TGF-
on transformed cell proliferation,
it modified the response in an adhesion-dependent manner. While we did
not identify the basis for these biological effects, preliminary
results from gene hybridization experiments argue against the notion
that there are differences in receptor levels in cells (N. Rane,
unpublished observations). Taken together, these observations prompt
further investigations of how RhoB may influence TGF-
signaling in
cells, particularly in the context of transformation or other stress- or disease-associated states.
 |
ACKNOWLEDGMENTS |
We thank B. Han and M. Mendelsohn for help in generating the
knockout mice and T. Jessell for support.
N.R. is the recipient of a postdoctoral fellowship from the U.S. Army
Breast Cancer Research Program. J.-P.L. is a recipient of a Burroughs
Wellcome Fund Career Award in the Biomedical Sciences. This study was
supported by NIH grant CA82222 to G.C.P.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Glenolden
Laboratory, DuPont Pharmaceuticals Company, 500 S. Ridgeway Ave., Rm.
265, Glenolden, PA 19036. Phone: (610) 237-7847. Fax: (610) 237-7937. E-mail: george.c.prendergast{at}dupontpharma.com.
Present address: Department of Neuroscience, University of Virginia
School of Medicine, Charlottesville, Va.
 |
REFERENCES |
| 1.
|
Adamson, P.,
H. F. Paterson, and A. Hall.
1992.
Intracellular localization of the p21rho proteins.
J. Cell Biol.
119:617-627[Abstract/Free Full Text].
|
| 2.
|
Bizub, D.,
A. W. Wood, and A. M. Skalka.
1986.
Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons.
Proc. Natl. Acad. Sci. USA
83:6048-6052[Abstract/Free Full Text].
|
| 3.
|
Du, W.,
P. F. Lebowitz, and G. C. Prendergast.
1999.
Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Mol. Cell. Biol.
19:1831-1840[Abstract/Free Full Text].
|
| 4.
|
Du, W., and G. C. Prendergast.
1999.
Geranylgeranylated RhoB mediates inhibition of human tumor cell growth by farnesyltransferase inhibitors.
Cancer Res.
59:5924-5928.
|
| 5.
|
Engel, M. E.,
P. K. Datta, and H. L. Moses.
1998.
RhoB is stabilized by transforming growth factor and antagonizes transcriptional activation.
J. Biol. Chem.
273:9921-9926[Abstract/Free Full Text].
|
| 6.
|
Fritz, G., and B. Kaina.
2000.
Ras-related GTPase RhoB forces alkylation-induced apoptotic cell death.
Biochem. Biophys. Res. Commun.
268:784-789[CrossRef][Medline].
|
| 7.
|
Fritz, G., and B. Kaina.
1997.
rhoB encoding a UV-inducible ras-related small GTP-binding protein is regulated by GTPases of the rho family and independent of JNK, ERK, and p38 MAP kinase.
J. Biol. Chem.
272:30637-30644[Abstract/Free Full Text].
|
| 8.
|
Fritz, G.,
B. Kaina, and K. Aktories.
1995.
The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments.
J. Biol. Chem.
270:25172-25177[Abstract/Free Full Text].
|
| 9.
|
Gampel, A.,
P. J. Parker, and H. Mellor.
1999.
Regulation of epidermal growth factor receptor traffic by the small GTPase RhoB.
Curr. Biol.
9:955-958[CrossRef][Medline].
|
| 10.
|
Ise, K.,
K. Nakamura,
K. Nakao,
S. Shimizu,
H. Harada,
T. Ichise,
J. Miyoshi,
Y. Gondo,
T. Ishikawa,
A. Aiba, and M. Katsuki.
2000.
Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis.
Oncogene
19:2151-2156.
|
| 11.
|
Jähner, D., and T. Hunter.
1991.
The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts.
Mol. Cell. Biol.
11:3682-3690[Abstract/Free Full Text].
|
| 12.
|
Jahner, D., and T. Hunter.
1991.
The stimulation of quiescent rat fibroblasts by v-src and v-fps oncogenic protein-tyrosine kinases leads to the induction of a subset of immediate early genes.
Oncogene
6:1259-1268[Medline].
|
| 13.
|
Khosravi-Far, R.,
P. A. Solski,
G. J. Clark,
M. S. Kinch, and C. J. Der.
1995.
Activation of Rac1, RhoA, and mitogen-activated protein kinase is required for Ras transformation.
Mol. Cell. Biol.
15:6443-6453[Abstract].
|
| 14.
|
Lebowitz, P.,
P. J. Casey,
G. C. Prendergast, and J. Thissen.
1997.
Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.
J. Biol. Chem.
272:15591-15594[Abstract/Free Full Text].
|
| 15.
|
Lebowitz, P., and G. C. Prendergast.
1998.
Functional interaction between RhoB and the transcription factor DB1.
Cell Adhes. Commun.
6:277-287[Medline].
|
| 16.
|
Lebowitz, P. F.,
D. Sakamuro, and G. C. Prendergast.
1997.
Farnesyltransferase inhibitors induce apoptosis in Ras-transformed cells denied substratum attachment.
Cancer Res.
57:708-713[Abstract/Free Full Text].
|
| 17.
|
Liu, A.-X.,
W. Du,
J.-P. Liu,
T. M. Jessell, and G. C. Prendergast.
2000.
RhoB alteration is necessary for the apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
Mol. Cell. Biol.
20:6105-6113[Abstract/Free Full Text].
|
| 18.
|
Liu, J. P., and T. M. Jessell.
1998.
A role for rhoB in the delamination of neural crest cells from the dorsal neural tube.
Development
125:5055-5067[Abstract].
|
| 19.
|
Mendrysa, S. M., and M. E. Perry.
2000.
The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress.
Mol. Cell. Biol.
20:2023-2030[Abstract/Free Full Text].
|
| 20.
|
Michaelson, D.,
J. Silletti,
G. Murphy,
P. D'Eustachio,
M. Rush, and M. R. Philips.
2001.
Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding.
J. Cell Biol.
152:111-126[Abstract/Free Full Text].
|
| 21.
|
Moustakas, A., and C. Stournaras.
1999.
Regulation of actin organisation by TGF-beta in H-ras-transformed fibroblasts.
J. Cell Sci.
112:1169-1179[Abstract].
|
| 22.
|
Prendergast, G. C.,
J. P. Davide,
S. J. deSolms,
E. A. Giuliani,
S. L. Graham,
J. B. Gibbs,
A. Oliff, and N. E. Kohl.
1994.
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.
Mol. Cell. Biol.
14:4193-4202[Abstract/Free Full Text].
|
| 23.
|
Prendergast, G. C.,
R. Khosravi-Far,
P. Solski,
H. Kurzawa,
P. Lebowitz, and C. J. Der.
1995.
Critical role of Rho in cell transformation by oncogenic Ras.
Oncogene
10:2289-2296[Medline].
|
| 24.
|
Qiu, R. G.,
J. Chen,
F. McCormick, and M. Symons.
1995.
A role for Rho in Ras transformation.
Proc. Natl. Acad. Sci. USA
92:11781-11785[Abstract/Free Full Text].
|
| 25.
|
Quintanilla, M.,
K. Brown,
M. Ramsden, and A. Balmain.
1986.
Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis.
Nature
322:78-80[Medline].
|
| 26.
|
Zalcman, G.,
V. Closson,
G. Linares-Cruz,
F. Leregours,
N. Honore,
A. Tavitian, and B. Olofsson.
1995.
Regulation of Ras-related RhoB protein expression during the cell cycle.
Oncogene
10:1935-1945[Medline].
|
| 27.
|
Zarbl, H.,
S. Sukumar,
A. V. Arthur,
D. Martin-Zanca, and M. Barbacid.
1985.
Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats.
Nature
315:382-385[CrossRef][Medline].
|
Molecular and Cellular Biology, October 2001, p. 6906-6912, Vol. 21, No. 20
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.20.6906-6912.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tahirovic, S., Bradke, F.
(2009). Neuronal Polarity. Cold Spring Harb. Perspect. Biol.
1: a001644-a001644
[Abstract]
[Full Text]
-
Bousquet, E., Mazieres, J., Privat, M., Rizzati, V., Casanova, A., Ledoux, A., Mery, E., Couderc, B., Favre, G., Pradines, A.
(2009). Loss of RhoB Expression Promotes Migration and Invasion of Human Bronchial Cells Via Activation of AKT1. Cancer Res.
69: 6092-6099
[Abstract]
[Full Text]
-
Garcia, M. C., Ray, D. M., Lackford, B., Rubino, M., Olden, K., Roberts, J. D.
(2009). Arachidonic Acid Stimulates Cell Adhesion through a Novel p38 MAPK-RhoA Signaling Pathway That Involves Heat Shock Protein 27. J. Biol. Chem.
284: 20936-20945
[Abstract]
[Full Text]
-
Kent, D. G., Copley, M. R., Benz, C., Wohrer, S., Dykstra, B. J., Ma, E., Cheyne, J., Zhao, Y., Bowie, M. B., Zhao, Y., Gasparetto, M., Delaney, A., Smith, C., Marra, M., Eaves, C. J.
(2009). Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood
113: 6342-6350
[Abstract]
[Full Text]
-
Warner, S. J., Longmore, G. D.
(2009). Distinct functions for Rho1 in maintaining adherens junctions and apical tension in remodeling epithelia. JCB
185: 1111-1125
[Abstract]
[Full Text]
-
Wang, X., Chen, Y., Wang, Y., Zhu, X., Ma, Y., Zhang, S., Lu, J.
(2009). Role of RHOB in the antiproliferative effect of glucocorticoid receptor on macrophage RAW264.7 cells. J Endocrinol
200: 35-43
[Abstract]
[Full Text]
-
Ramalingam, A., Duhadaway, J. B., Sutanto-Ward, E., Wang, Y., Dinchuk, J., Huang, M., Donover, P. S., Boulden, J., McNally, L. M., Soler, A. P., Muller, A. J., Duncan, M. K., Prendergast, G. C.
(2008). Bin3 Deletion Causes Cataracts and Increased Susceptibility to Lymphoma during Aging. Cancer Res.
68: 1683-1690
[Abstract]
[Full Text]
-
Huang, M., DuHadaway, J. B., Prendergast, G. C., Laury-Kleintop, L. D.
(2007). RhoB Regulates PDGFR- Trafficking and Signaling in Vascular Smooth Muscle Cells. Arterioscler. Thromb. Vasc. Bio.
27: 2597-2605
[Abstract]
[Full Text]
-
Boureux, A., Vignal, E., Faure, S., Fort, P.
(2007). Evolution of the Rho Family of Ras-Like GTPases in Eukaryotes. Mol Biol Evol
24: 203-216
[Abstract]
[Full Text]
-
O'Donnell, S. M., Holm, G. H., Pierce, J. M., Tian, B., Watson, M. J., Chari, R. S., Ballard, D. W., Brasier, A. R., Dermody, T. S.
(2006). Identification of an NF-{kappa}B-Dependent Gene Network in Cells Infected by Mammalian Reovirus. J. Virol.
80: 1077-1086
[Abstract]
[Full Text]
-
Canguilhem, B., Pradines, A., Baudouin, C., Boby, C., Lajoie-Mazenc, I., Charveron, M., Favre, G.
(2005). RhoB Protects Human Keratinocytes from UVB-induced Apoptosis through Epidermal Growth Factor Receptor Signaling. J. Biol. Chem.
280: 43257-43263
[Abstract]
[Full Text]
-
Suzuki, C., Daigo, Y., Ishikawa, N., Kato, T., Hayama, S., Ito, T., Tsuchiya, E., Nakamura, Y.
(2005). ANLN Plays a Critical Role in Human Lung Carcinogenesis through the Activation of RHOA and by Involvement in the Phosphoinositide 3-Kinase/AKT Pathway. Cancer Res.
65: 11314-11325
[Abstract]
[Full Text]
-
Pan, J., Yeung, S.-C. J.
(2005). Recent Advances in Understanding the Antineoplastic Mechanisms of Farnesyltransferase Inhibitors. Cancer Res.
65: 9109-9112
[Abstract]
[Full Text]
-
Hakem, A., Sanchez-Sweatman, O., You-Ten, A., Duncan, G., Wakeham, A., Khokha, R., Mak, T. W.
(2005). RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev.
19: 1974-1979
[Abstract]
[Full Text]
-
Fernandez-Borja, M., Janssen, L., Verwoerd, D., Hordijk, P., Neefjes, J.
(2005). RhoB regulates endosome transport by promoting actin assembly on endosomal membranes through Dia1. J. Cell Sci.
118: 2661-2670
[Abstract]
[Full Text]
-
Wang, D.-A., Sebti, S. M.
(2005). Palmitoylated Cysteine 192 Is Required for RhoB Tumor-suppressive and Apoptotic Activities. J. Biol. Chem.
280: 19243-19249
[Abstract]
[Full Text]
-
Vardouli, L., Moustakas, A., Stournaras, C.
(2005). LIM-kinase 2 and Cofilin Phosphorylation Mediate Actin Cytoskeleton Reorganization Induced by Transforming Growth Factor-{beta}. J. Biol. Chem.
280: 11448-11457
[Abstract]
[Full Text]
-
Kamasani, U., Huang, M., DuHadaway, J. B., Prochownik, E. V., Donover, P. S., Prendergast, G. C.
(2004). Cyclin B1 Is a Critical Target of RhoB in the Cell Suicide Program Triggered by Farnesyl Transferase Inhibition. Cancer Res.
64: 8389-8396
[Abstract]
[Full Text]
-
Wherlock, M., Gampel, A., Futter, C., Mellor, H.
(2004). Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J. Cell Sci.
117: 3221-3231
[Abstract]
[Full Text]
-
Jiang, K., Sun, J., Cheng, J., Djeu, J. Y., Wei, S., Sebti, S.
(2004). Akt Mediates Ras Downregulation of RhoB, a Suppressor of Transformation, Invasion, and Metastasis. Mol. Cell. Biol.
24: 5565-5576
[Abstract]
[Full Text]
-
Mazieres, J., Antonia, T., Daste, G., Muro-Cacho, C., Berchery, D., Tillement, V., Pradines, A., Sebti, S., Favre, G.
(2004). Loss of RhoB Expression in Human Lung Cancer Progression. Clin. Cancer Res.
10: 2742-2750
[Abstract]
[Full Text]
-
Wennerberg, K., Der, C. J.
(2004). Rho-family GTPases: it's not only Rac and Rho (and I like it). J. Cell Sci.
117: 1301-1312
[Abstract]
[Full Text]
-
Chauhan, S., Kunz, S., Davis, K., Roberts, J., Martin, G., Demetriou, M. C., Sroka, T. C., Cress, A. E., Miesfeld, R. L.
(2004). Androgen Control of Cell Proliferation and Cytoskeletal Reorganization in Human Fibrosarcoma Cells: ROLE OF RhoB SIGNALING. J. Biol. Chem.
279: 937-944
[Abstract]
[Full Text]
-
Holstein, S. A., Wohlford-Lenane, C. L., Hohl, R. J.
(2002). Consequences of Mevalonate Depletion. DIFFERENTIAL TRANSCRIPTIONAL, TRANSLATIONAL, AND POST-TRANSLATIONAL UP-REGULATION OF Ras, Rap1a, RhoA, AND RhoB. J. Biol. Chem.
277: 10678-10682
[Abstract]
[Full Text]